MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma

Journal of Lipid Research

Volumn 54, Issue 7, 2013, Pages 1877-1883

  Wiesner, Philipp ^a   Tafelmeier, Maria ^b   Chittka, Dominik ^b   Choi, Soo Ho ^a   Zhang, Li ^c   Byun, YoungSup ^d   Almazan, Felicidad ^a   Yang, Xiaohong ^a   Iqbal, Navaid ^e   Chowdhury, Punam ^e   Maisel, Alan ^e   Witztum, Joseph L ^a   Handel, Tracy M ^c   Tsimikas, Sotirios ^a   Miller, Yury I ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Inje University College of Medicine   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemokine (C C motif) ligand 2; Monocyte chemoattractant protein 1; Monocyte migration; Oxidized low density lipoprotein

Indexed keywords

LIPOPROTEIN A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E06; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION;

CHEMOKINE (C-C MOTIF) LIGAND 2; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MONOCYTE MIGRATION; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMALS; BINDING SITES; CHEMOKINE CCL2; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECOMBINANT PROTEINS;

EID: 84878959653     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M036343     Document Type: Article

References (36)

1. Salanga, C. L., and T. M. Handel. 2011. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317: 590-601.
2. Weber, C., and H. Noels. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17: 1410-1422.
3. Boring, L., J. Gosling, M. Cleary, and I. F. Charo. 1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394: 894-897. (Pubitemid 28410911)
4. de Lemos, J. A., D. A. Morrow, M. S. Sabatine, S. A. Murphy, C. M. Gibson, E. M. Antman, C. H. McCabe, C. P. Cannon, and E. Braunwald. 2003. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 107: 690-695. (Pubitemid 36222595)
5. Deo, R., A. Khera, D. K. McGuire, S. A. Murphy, J. P. Meo Neto, D. A. Morrow, and J. A. de Lemos. 2004. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 44: 1812-1818.
6. de Lemos, J. A., D. A. Morrow, M. A. Blazing, P. Jarolim, S. D. Wiviott, M. S. Sabatine, R. M. Califf, and E. Braunwald. 2007. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J. Am. Coll. Cardiol. 50: 2117-2124. (Pubitemid 350117348)
7. Proudfoot, A. E., T. M. Handel, Z. Johnson, E. K. Lau, P. LiWang, I. Clark-Lewis, F. Borlat, T. N. Wells, and M. H. Kosco-Vilbois. 2003. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA. 100: 1885-1890. (Pubitemid 36254543)
8. Weber, K. S., P. von Hundelshausen, I. Clark-Lewis, P. C. Weber, and C. Weber. 1999. Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur. J. Immunol. 29: 700-712. (Pubitemid 29078533)
9. Lau, E. K., C. D. Paavola, Z. Johnson, J. P. Gaudry, E. Geretti, F. Borlat, A. J. Kungl, A. E. Proudfoot, and T. M. Handel. 2004. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J. Biol. Chem. 279: 22294-22305. (Pubitemid 38679426)
10. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis. The road ahead. Cell. 104: 503-516.
11. Reddy, S., S. Hama, V. Grijalva, K. Hassan, R. Mottahedeh, G. Hough, D. J. Wadleigh, M. Navab, and A. M. Fogelman. 2001. Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells. J. Biol. Chem. 276: 17030-17035.
12. Havel, R. J., J. H. Bragdon, and H. A. Eder. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
13. Miller, Y. I., S. Viriyakosol, C. J. Binder, J. R. Feramisco, T. N. Kirkland, and J. L. Witztum. 2003. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278: 1561-1568. (Pubitemid 36801384)
14. Schneider, M., J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al. 2005. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J. Lipid Res. 46: 769-778. (Pubitemid 43073287)
15. Merki, E., M. J. Graham, A. E. Mullick, E. R. Miller, R. M. Crooke, R. E. Pitas, J. L. Witztum, and S. Tsimikas. 2008. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 118: 743-753.
16. Merki, E., M. Graham, A. Taleb, G. Leibundgut, X. Yang, E. R. Miller, W. Fu, A. E. Mullick, R. Lee, P. Willeit, et al. 2011. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 57: 1611-1621.
17. Paavola, C. D., S. Hemmerich, D. Grunberger, I. Polsky, A. Bloom, R. Freedman, M. Mulkins, S. Bhakta, D. McCarley, L. Wiesent, et al. 1998. Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J. Biol. Chem. 273: 33157-33165. (Pubitemid 29005686)
18. Hörkkö, S., D. A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J. A. Berliner, P. Friedman, E. A. Dennis, L. K. Curtiss, et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128. (Pubitemid 29031170)
19. Young, S. G., J. L. Witztum, D. C. Casal, L. K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6: 178-188. (Pubitemid 16024127)
20. Tsimikas, S., H. K. Lau, K. R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss. 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 109: 3164-3170.
21. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Horkko, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607. (Pubitemid 27224791)
22. Cherney, R. J., R. Mo, D. T. Meyer, D. J. Nelson, Y. C. Lo, G. Yang, P. A. Scherle, S. Mandlekar, Z. R. Wasserman, H. Jezak, et al. 2008. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J. Med. Chem. 51: 721-724. (Pubitemid 351304681)
23. Kredel, S., M. Wolff, S. Hobbie, M. Bieler, P. Gierschik, and R. Heilker. 2011. High-content analysis of CCR2 antagonists on human primary monocytes. J. Biomol. Screen. 16: 683-693.
24. Bergmark, C., A. Dewan, A. Orsoni, E. Merki, E. R. Miller, M. J. Shin, C. J. Binder, S. Horkko, R. M. Krauss, M. J. Chapman, et al. 2008. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49: 2230-2239.
25. Tsimikas, S., and J. L. Hall. 2012. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60: 716-721.
26. Taleb, A., J. L. Witztum, and S. Tsimikas. 2011. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark. Med. 5: 673-694.
27. Miller, Y. I., S-H. Choi, P. Wiesner, L. Fang, R. Harkewicz, K. Hartvigsen, A. Boullier, A. Gonen, C. J. Diehl, X. Que, et al. 2011. Oxidation-specific epitopes are danger associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108: 235-248.
28. Steinberg, D., and J. L. Witztum. 2010. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30: 2311-2316.
29. Lee, S., K. G. Birukov, C. E. Romanoski, J. R. Springstead, A. J. Lusis, and J. A. Berliner. 2012. Role of phospholipid oxidation products in atherosclerosis. Circ. Res. 111: 778-799.
30. Adamson, S., and N. Leitinger. 2011. Phenotypic modulation of macrophages in response to plaque lipids. Curr. Opin. Lipidol. 22: 335-342.
31. Quinn, M. T., S. Parthasarathy, L. G. Fong, and D. Steinberg. 1987. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84: 2995-2998. (Pubitemid 17064764)
32. Quinn, M. T., S. Parthasarathy, and D. Steinberg. 1988. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. USA. 85: 2805-2809.
33. van Dijk, R. A., F. Kolodgie, A. Ravandi, G. Leibundgut, P. P. Hu, A. Prasad, E. Mahmud, E. Dennis, L. K. Curtiss, J. L. Witztum, et al. 2012. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J. Lipid Res. 53: 2773-2790.
34. Dangas, G., R. Mehran, P. C. Harpel, S. K. Sharma, S. M. Marcovina, G. Dube, J. A. Ambrose, and J. T. Fallon. 1998. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J. Am. Coll. Cardiol. 32: 2035-2042. (Pubitemid 29010473)
35. Seimon, T. A., M. J. Nadolski, X. Liao, J. Magallon, M. Nguyen, N. T. Feric, M. L. Koschinsky, R. Harkewicz, J. L. Witztum, S. Tsimikas, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12: 467-482.
36. Dubé, J. B., M. B. Boffa, R. A. Hegele, and M. L. Koschinsky. 2012. Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23: 133-140.